Clinical Trial

A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy volunteers. We also want to learn about the safety of WD-1603. The main question we want to answer is: * How does the body process WD-1603 when it is taken by different time intervals? What will participants do? * Participants will take one tablet of WD-1603 twice a day on three separate days. * On each dosing day, the two doses will be spaced different hours apart. * Between each dosing day, there will be a rest period of up to 7 days.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-09
Trial Details
NCT Number NCT07442591
Lead Sponsor Shanghai WD Pharmaceutical Co., Ltd.
Collaborators: Shanghai Xuhui Central Hospital, BalGenSource Medical Technology Co. Ltd., Shanghai Xihua Scientific Co., Ltd., Shanghai BioGuider Medical Technology Co., Ltd.
Conditions Healhty
Enrollment 12 participants
Start Date 2026-03-24
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-08